ArticleOncoimmunology2013
Molecular profiling of tumor-specific T
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Identification of tumor-specific T cell signature predicting cancer immunotherapy response in bladder cancer by multi-omics analysis and experimental verification.Cancer cell international · 2024Article
- Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.Frontiers in immunology · 2022Article
- CD4Cancer immunology, immunotherapy : CII · 2019Review
- Programmed death-1 controls T cell survival by regulating oxidative metabolism.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Differential protein network analysis of the immune cell lineage.BioMed research international · 2014Article
- Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy.Oncoimmunology · 2014Article
- How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Frontiers in immunology · 2014Review
- Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.Frontiers in immunology · 2014Review
- CD30: from basic research to cancer therapy.Immunologic research · 2013Review
- Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The central role of tumor-specific T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.